Redeye comments on Annexin’s Q3 report and recent events.
Taaleri’s Q3 2025 continuing earnings of EUR 10.1m increased by 4% y/y and came 5% above our estimat...
Redeye has revised its estimates following Heliospectra’s Q3 2025 report.
Fastpartners hyresintäkter och driftnetto minskade för det tredje kvartalet drivet av avyttringar sa...
Eastnine levererar för det tredje kvartalet en stark rapport med rekordresultat.
Redeye returns with a more optimistic outlook following Polygiene’s Q3 2025 report, which presented ...
Although Consti posted good growth figures in Q3 considering market conditions, margins were lower t...
Aspo reports Q3 results on Nov 3. In our view the midpoint of FY’25 comparable EBITA guidance remain...
Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not me...
Redeye comments on Nitro Games Q3-results which came in above our expectations supported by both str...
Redeye updates its estimates and valuation after Lagercrantz’s Q2 2025/2026 report.
Redeye updates its estimates and valuation after Lifco’s Q3 2025 report.
Redeye is making some downward adjustments to our estimates and valuation, following the Q3 report a...
Redeye updates its estimates and valuation following MedCap’s Q3 2025 report.
A trade war between the US and India created headwind for Incap's operations in Q3.
Organic growth returned in Q3 y/y after some challenging years, but net sales and EBIT were slightly...
Redeye has updated its estimates and valuation for Sleep Cycle following the Q3 2025 report, which s...
Redeye updates on Invisio following the company’s Q3-results which came in below our expectations ow...
Redeye retains its positive view of Avensia despite slightly lowering our Base Case and forecasts.
Redeye takes a slightly more positive view of Hexatronic following the Q3 report, showing stronger m...
